ATA14642003A - Impfstoff für die alzheimer-krankheit - Google Patents

Impfstoff für die alzheimer-krankheit

Info

Publication number
ATA14642003A
ATA14642003A AT0146403A AT14642003A ATA14642003A AT A14642003 A ATA14642003 A AT A14642003A AT 0146403 A AT0146403 A AT 0146403A AT 14642003 A AT14642003 A AT 14642003A AT A14642003 A ATA14642003 A AT A14642003A
Authority
AT
Austria
Prior art keywords
arg
glu
asp
tyr
phe
Prior art date
Application number
AT0146403A
Other languages
English (en)
Other versions
AT413945B (de
Original Assignee
Mattner Frank Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0146403A priority Critical patent/AT413945B/de
Application filed by Mattner Frank Dr filed Critical Mattner Frank Dr
Priority to DE602004025668T priority patent/DE602004025668D1/de
Priority to SI200431399T priority patent/SI1583774T1/sl
Priority to AT05107898T priority patent/ATE376559T1/de
Priority to JP2006500553A priority patent/JP4547373B2/ja
Priority to EP05107898A priority patent/EP1679319B1/de
Priority to PCT/EP2004/000162 priority patent/WO2004062556A2/en
Priority to ES04701585T priority patent/ES2339447T3/es
Priority to AT04701585T priority patent/ATE458753T1/de
Priority to DK04701585.4T priority patent/DK1583774T3/da
Priority to PL378333A priority patent/PL209989B1/pl
Priority to DK05107898T priority patent/DK1679319T3/da
Priority to HK06111905.5A priority patent/HK1091499B/xx
Priority to CN2011103110387A priority patent/CN102526699A/zh
Priority to PT05107898T priority patent/PT1679319E/pt
Priority to US10/540,551 priority patent/US7732568B2/en
Priority to EP04701585A priority patent/EP1583774B1/de
Priority to ES05107898T priority patent/ES2296084T3/es
Priority to PT04701585T priority patent/PT1583774E/pt
Priority to DE602004009705T priority patent/DE602004009705T2/de
Priority to AU2004204349A priority patent/AU2004204349B2/en
Priority to SI200430549T priority patent/SI1679319T1/sl
Priority to CN200480002213.2A priority patent/CN1826354B/zh
Priority to CA2513218A priority patent/CA2513218C/en
Publication of ATA14642003A publication Critical patent/ATA14642003A/de
Application granted granted Critical
Publication of AT413945B publication Critical patent/AT413945B/de
Priority to CY20081100069T priority patent/CY1107146T1/el
Priority to JP2010051012A priority patent/JP5282058B2/ja
Priority to US12/752,451 priority patent/US20110015131A1/en
Priority to CY20101100399T priority patent/CY1110634T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
AT0146403A 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit AT413945B (de)

Priority Applications (28)

Application Number Priority Date Filing Date Title
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit
US10/540,551 US7732568B2 (en) 2003-01-14 2004-01-13 Methods for preventing and treating Alzheimer's disease
AT05107898T ATE376559T1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit
JP2006500553A JP4547373B2 (ja) 2003-01-14 2004-01-13 アルツハイマー病の予防および治療方法
EP05107898A EP1679319B1 (de) 2003-01-14 2004-01-13 Methoden der Verhinderung und Behandlung der Alzheimer'schen Krankheit
PCT/EP2004/000162 WO2004062556A2 (en) 2003-01-14 2004-01-13 Methods for preventing and treating alzheimer’s disease (ad)
ES04701585T ES2339447T3 (es) 2003-01-14 2004-01-13 Procedimiento para prevenir y tratar la enfermedad de alzehimer (ad).
AT04701585T ATE458753T1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit
DK04701585.4T DK1583774T3 (da) 2003-01-14 2004-01-13 Fremgangsmåder til forebyggelse og behandling af alzheimers sygdom
PL378333A PL209989B1 (pl) 2003-01-14 2004-01-13 Zastosowanie związku peptydowego oraz szczepionka przeciwko chorobie Alzheimera
DK05107898T DK1679319T3 (da) 2003-01-14 2004-01-13 Fremgangsmåde til forebyggelse og behandling af Alzheimers sygdom (AD)
HK06111905.5A HK1091499B (en) 2003-01-14 2004-01-13 Methods for preventing and treating alzheimer's disease (ad)
CN2011103110387A CN102526699A (zh) 2003-01-14 2004-01-13 预防和治疗阿尔茨海默病(ad)的方法
PT05107898T PT1679319E (pt) 2003-01-14 2004-01-13 Métodos para a prevenção e o tratamento da doença de alzheimer (ad)
DE602004025668T DE602004025668D1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit
SI200430549T SI1679319T1 (sl) 2003-01-14 2004-01-13 Postopki za preprecevanje in zdravljenje Alzheimerjeve bolezni
CA2513218A CA2513218C (en) 2003-01-14 2004-01-13 Peptides and uses thereof for preventing and treating alzheimer's disease(ad)
PT04701585T PT1583774E (pt) 2003-01-14 2004-01-13 Métodos para prevenção e tratamento de doença de alzheimer (da)
DE602004009705T DE602004009705T2 (de) 2003-01-14 2004-01-13 Methoden der Verhinderung und Behandlung der Alzheimer'schen Krankheit
AU2004204349A AU2004204349B2 (en) 2003-01-14 2004-01-13 Methods for preventing and treating Alzheimer's disease (AD)
SI200431399T SI1583774T1 (sl) 2003-01-14 2004-01-13 Postopki za preprečevanje in zdravljenje Alzheimerjeve bolezni AD
CN200480002213.2A CN1826354B (zh) 2003-01-14 2004-01-13 预防和治疗阿尔茨海默病(ad)的方法
ES05107898T ES2296084T3 (es) 2003-01-14 2004-01-13 Procedimientos para la prevencion y el tratamiento de la enfermedad de alzheimer (ea).
EP04701585A EP1583774B1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit
CY20081100069T CY1107146T1 (el) 2003-01-14 2008-01-17 Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
JP2010051012A JP5282058B2 (ja) 2003-01-14 2010-03-08 アルツハイマー病の予防および治療方法
US12/752,451 US20110015131A1 (en) 2003-01-14 2010-04-01 Methods for preventing and treating alzheimer's disease (ad)
CY20101100399T CY1110634T1 (el) 2003-01-14 2010-05-07 Μεθοδοι προληψης και θεραπειας της νοσου του αλτσχαϊμερ (ad)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT362003 2003-01-14
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit

Publications (2)

Publication Number Publication Date
ATA14642003A true ATA14642003A (de) 2005-11-15
AT413945B AT413945B (de) 2006-07-15

Family

ID=32714004

Family Applications (3)

Application Number Title Priority Date Filing Date
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit
AT04701585T ATE458753T1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit
AT05107898T ATE376559T1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT04701585T ATE458753T1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit
AT05107898T ATE376559T1 (de) 2003-01-14 2004-01-13 Methoden der verhinderung und behandlung der alzheimer'schen krankheit

Country Status (14)

Country Link
US (2) US7732568B2 (de)
EP (2) EP1679319B1 (de)
JP (2) JP4547373B2 (de)
CN (2) CN102526699A (de)
AT (3) AT413945B (de)
CA (1) CA2513218C (de)
CY (2) CY1107146T1 (de)
DE (2) DE602004009705T2 (de)
DK (2) DK1679319T3 (de)
ES (2) ES2339447T3 (de)
PL (1) PL209989B1 (de)
PT (2) PT1679319E (de)
SI (1) SI1583774T1 (de)
WO (1) WO2004062556A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
EP1711208A2 (de) * 2004-01-28 2006-10-18 Curix APS Konjugate von amyloid-proteinen als impfstoffe gegen amyloid-bedingte erkrankungen
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
EP1959996A2 (de) * 2005-12-12 2008-08-27 AC Immune S.A. Monoklonaler antikörper
EP1878747A1 (de) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-hergestellte Antikörper
EP2046833B9 (de) * 2006-07-14 2014-02-19 AC Immune S.A. Humanisierter antikörper gegen amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
ES2529174T3 (es) * 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US20100297013A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
AU2008311367B2 (en) * 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
US8586706B2 (en) * 2007-10-25 2013-11-19 Kagoshima University Peptide vaccine using mimic molecules of amyloid β peptide
EP2224000B1 (de) * 2007-10-29 2020-05-13 TAO Health Life Pharma Co., Ltd. Antikörper und dessen verwendung
WO2009128948A1 (en) 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
CN102123726A (zh) * 2008-06-12 2011-07-13 阿费里斯股份公司 用于治疗与帕金森氏病有关的症状的化合物
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (de) 2010-07-30 2017-07-26 AC Immune S.A. Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
PT2579042E (pt) 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
EP2787347A1 (de) 2013-04-03 2014-10-08 Affiris AG Verfahren zur Erkennung von Aß-spezifischen Antikörpern in einer biologischen Probe
US10381614B2 (en) * 2013-04-17 2019-08-13 Samsung Sdi Co., Ltd. Battery module
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
RU2734924C2 (ru) 2015-11-03 2020-10-26 Аффирис Аг Способ вакцинации против аутоантигена у пациента-человека
CN105237628B (zh) * 2015-11-17 2018-08-07 南开大学 一种用于治疗阿尔兹海默症的多肽
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (de) 2020-05-26 2024-11-13 TrueBinding, Inc. Verfahren zur behandlung von entzündungskrankheiten durch galectin-3-blockierung
EP4486389A1 (de) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG Konjugat mit mindestens einem beta-glucan

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9022190D0 (en) * 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6088993A (en) 1999-02-05 2000-07-18 Irace; Francisco D. Closure system
EP1156825A2 (de) 1999-02-25 2001-11-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogene enthaltend ein peptid und einen von h.influenzae protein d abstammenden träger
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
AU784568B2 (en) * 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
MXPA02008616A (es) * 2000-03-03 2003-02-24 Smithkline Beecham Biolog Vacuna para el tratamiento de la arterosclerosis.
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
ES2276732T3 (es) 2001-09-03 2007-07-01 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Mimotopos de antigenos y vacuna contra enfermedades cancerosas.
ES2276895T3 (es) * 2002-05-07 2007-07-01 Institut Pasteur Cribado de peptidos qque inhiben la union de pp1c a las proteinas bcl-2, bcl-xi y bcl-w.

Also Published As

Publication number Publication date
PL209989B1 (pl) 2011-11-30
CY1110634T1 (el) 2015-04-29
CN102526699A (zh) 2012-07-04
EP1583774B1 (de) 2010-02-24
DE602004009705T2 (de) 2008-06-05
AU2004204349A1 (en) 2004-07-29
US7732568B2 (en) 2010-06-08
JP2010174024A (ja) 2010-08-12
JP4547373B2 (ja) 2010-09-22
AT413945B (de) 2006-07-15
DE602004025668D1 (de) 2010-04-08
PL378333A1 (pl) 2006-03-20
JP5282058B2 (ja) 2013-09-04
WO2004062556A8 (en) 2004-10-21
CA2513218C (en) 2013-06-25
ATE458753T1 (de) 2010-03-15
DK1583774T3 (da) 2010-05-03
ATE376559T1 (de) 2007-11-15
DK1679319T3 (da) 2008-01-28
PT1583774E (pt) 2010-04-07
US20110015131A1 (en) 2011-01-20
HK1091499A1 (en) 2007-01-19
SI1583774T1 (sl) 2010-06-30
CN1826354A (zh) 2006-08-30
WO2004062556A3 (en) 2004-09-16
ES2339447T3 (es) 2010-05-20
JP2006515876A (ja) 2006-06-08
CA2513218A1 (en) 2004-07-29
PT1679319E (pt) 2008-01-10
DE602004009705D1 (de) 2007-12-06
ES2339447T8 (es) 2011-05-26
ES2296084T3 (es) 2008-04-16
CY1107146T1 (el) 2012-05-23
EP1583774A2 (de) 2005-10-12
EP1679319B1 (de) 2007-10-24
CN1826354B (zh) 2014-01-08
US20060111301A1 (en) 2006-05-25
EP1679319A1 (de) 2006-07-12
WO2004062556A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
ATA14642003A (de) Impfstoff für die alzheimer-krankheit
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
AT500379B1 (de) Tau-proteine
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
BRPI0415230A (pt) anticorpo biespecìfico de substituição de proteìnas funcionais
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
EP2292646A3 (de) Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
NO20025064L (no) RGO koblet til peptider
EP1023906A4 (de) Verstärker für antikörper gegen lymphoiden tumor
SE9800504D0 (sv) Novel peptide/protein, diagnostic reagent and kit for detection of rickettsiosis
WO2004053117A3 (en) Serine protease
DE50111112D1 (de) Hyphenspezifische faktoren aus candida albicans
ATE512981T1 (de) Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen
WO2006038101A3 (en) Novel cancer associated antibodies and antigens and their use in cancer diagnosis
ATE364081T1 (de) Identifizierung von ses-1 aus c. elegans sowie dessen verwendung
DE60122721D1 (de) Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
WO2002070560A3 (en) Nuclear hormone receptor ligand binding domain
WO2004062462A8 (en) Monclonal anitbodies to rna binding protein gw182
WO2002050116A3 (en) Adhesion molecule protein

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
PC Change of the owner

Owner name: WALTER SCHMIDT, AT

Effective date: 20170329

Owner name: FRANK MATTNER, AT

Effective date: 20170329

MM01 Lapse because of not paying annual fees

Effective date: 20191115